41 patents
Utility
Ras Inhibitors
23 Nov 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
Filed: 6 Feb 23
Utility
Bicyclic Heteroaryl Compounds and Uses Thereof
16 Nov 23
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
Filed: 11 Oct 22
Utility
Ras Inhibitors
28 Sep 23
The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Andreas Buckl, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Christopher Semko
Filed: 7 Oct 22
Utility
Methods for Delaying, Preventing, and Treating Acquired Resistance to Ras Inhibitors
27 Jul 23
The present disclosure relates to compositions and methods for the treatment of diseases or disorders (e.g., cancer) with bi-steric inhibitors of mTOR in combination with RAS inhibitors.
Mallika SINGH, Jingjing JIANG, Yu Chi YANG, James W. EVANS, Christopher J. SCHULZE
Filed: 21 Jun 21
Utility
Ras Inhibitors
27 Jul 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James Cregg, Adrian L. Gill, James Aggen, G. Leslie Burnett, Jennifer Pitzen, Andreas Buckl, John E. Knox, Yang Liu
Filed: 30 Jan 23
Utility
Ras Inhibitors
20 Jul 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Naing AAY, G. Leslie BURNETT, James CREGG, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Yang LIU, Andreas BUCKL, Bianca Jennifer LEE, David E. WILDES, Meghan A. RICE, Mallika SINGH
Filed: 23 Mar 23
Utility
CorrectedBicyclic Heteroaryl Compounds and Uses Thereof
11 May 23
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
Andreas BUCKL, James Joseph CREGG, Naing AAY, Arlyn A. TAMBO-ONG, Elena S. KOLTUN, Adrian Liam GILL, Severin THOMPSON, Micah J Gliedt
Filed: 2 Mar 20
Utility
Ras Inhibitors
6 Apr 23
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
Filed: 5 May 22
Utility
Rapamycin Analogs As Mtor Inhibitors
30 Mar 23
The present disclosure relates to mTOR inhibitors.
James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
Filed: 11 Mar 22
Utility
Bicyclic Heterocyclyl Compounds and Uses Thereof
30 Mar 23
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
James Joseph CREGG, Andreas BUCKL, Naing AAY, Arlyn A. TAMBO-ONG, Elena S. KOLTUN, Adrian Liam GILL, Severin THOMPSON, Micah J. Gliedt
Filed: 2 Mar 20
Utility
Covalent Ras Inhibitors and Uses Thereof
30 Mar 23
The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
Jennifer PITZEN, James AGGEN, G. Leslie BURNETT, Adrian L. GILL, Christopher SEMKO, Anne V. EDWARDS, Micah James GLIEDT, Gert KISS, Ashutosh JOGALEKAR, John E. KNOX, Andreas BUCKL, Elena S. KOLTUN
Filed: 26 May 22
Utility
SHP2 Inhibitor Dosing and Methods of Treating Cancer
9 Mar 23
Disclosed are SHP2 inhibitor compositions and methods of treating diseases or disorders using an intermittent dosing schedule.
Steve Kelsey, Mallika Singh, Xiaolin Wang, Zhengping Wang
Filed: 30 Jun 22
Utility
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
23 Feb 23
The present disclosure relates to mTOR inhibitors.
Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
Filed: 29 Apr 22
Utility
Ras Inhibitors
15 Dec 22
The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Andreas BUCKL, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN, Christopher SEMKO
Filed: 5 May 22
Utility
C26-LINKED Rapamycin Analogs As Mtor Inhibitors
27 Oct 22
The present disclosure relates to mTOR inhibitors.
Christopher Michael SEMKO, Gang WANG, G. Leslie BURNETT, James Bradley AGGEN, Gert KISS, James Joseph CREGG, Micah James Evans GLIEDT, Jennifer PITZEN, Julie Chu-Li LEE, Walter WON, Arun P. THOTTUMKARA, Adrian Liam GILL
Filed: 30 Oct 20
Utility
Solid Forms of {6-[(2-AMINO-3-CHLOROPYRIDIN-4-YL)SULFANYL]-3-[(3S,4S)-4-AMINO-3-METHYL-2-OXA-8-AZASPIRO[4.5]DECAN-8-YL]-5-METHYLPYRAZIN-2-YL}METHANOL, a SHP2 Inhibitor
22 Sep 22
The present disclosure relates to crystalline solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, or a pharmaceutically acceptable salt thereof, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
Shaoling LI, Steven G. BALLMER
Filed: 29 Nov 21
Utility
Compounds That Participate In Cooperative Binding and Uses Thereof
12 May 22
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein).
Gregory Lawrence VERDINE, M. James NICHOLS, Dylan Talbot STILES, Neville John ANTHONY, Brian Roger BOWMAN, Mathew Edward SOWA, Sharon Ann TOWNSON
Filed: 10 Jun 21
Utility
Compounds That Participate In Cooperative Binding and Uses Thereof
12 May 22
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250.
Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
Filed: 11 Jun 21
Utility
Bicyclic Heteroaryl Compounds and Uses Thereof
5 May 22
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease.
Andreas BUCKL, James Joseph CREGG, Naing AAY, Arlyn A. TAMBO-ONG, Elena S. KOLTUN, Adrian Liam GILL, Severin THOMPSON, Micah J Gliedt
Filed: 2 Mar 20
Utility
Identifying New Therapeutic Agents
17 Mar 22
Disclosed herein are methods for identifying novel drug candidates.
Gregory L. VERDINE, David W. WHITE, David M. ARMISTEAD, Deborah J. PALESTRANT, Brian Y. CHOW, Chris K. VARMA, Mathew Edward SOWA
Filed: 21 Dec 20